News

The company’s loss from operations was $7.39m, compared to $5.76m for the same period last year. Total operating expenses for the first quarter ended 31 March 2011 were

The Phase I study will investigate the safety, immunological and the biological effect of the drug in patients who are suffering from melanoma. Through intratumoral injection, Ad-RTS-IL-12 employs

SFP is an investigational, continuous iron therapy in late-stage clinical development designed to treat end-stage renal disease (ESRD) patients. Clinical trial data suggests that SFP, delivered via dialysate

As per the terms of the agreement, all the companies will jointly organize research and development to evaluate the feasibility of developing various ophthalmic solutions applying Activus Pure

Brightwell Technologies is a provider in Micro-Flow Imaging (MFI), an analytical technique used to detect particles and aggregates in protein-based therapeutics. Cell Biosciences has raised $13m in a

In the trial, the companies will investigate the safety of Lu AA21004 (5 and 10 mg) compared to placebo. The primary endpoint of the Phase III trial is

The company’s loss from operations was $3.56m, compared to $4.57m for the same period last year. Total operating expenses for the first quarter ended 31 March 2011 were

The increase was primarily due to the amortization of deferred revenue from the upfront license fee received from our collaboration agreement with Norgine entered into in June 2010.

The drug pricing feature allows members to quickly determine the cost of their prescriptions, identify lower-cost alternatives and compare the costs of the prescription from multiple pharmacies and